Selective 5-HT1B/1D receptor agonist (triptan) for acute migraine — cranial vasoconstriction and trigeminal inhibition; also binds 5-HT1F. Active N-desmethyl metabolite.
Half-Life & Elimination Curve (PO: 3h)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
0×t½0h100%(1.45 µg/L)
1×t½3h50%(0.726 µg/L)
2×t½6h25%(0.363 µg/L)
3×t½9h12.5%(0.181 µg/L)
4×t½12h6.3%(0.0907 µg/L)
5×t½15h3.1%(0.0454 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.47h
Est. Peak (Cmax)1.45 µg/L
Clearance (CL)113 L/h
97% Washout (5×t½)15h
Dosing Guidelines
Oral (PO): Typical 2.5 mg (Range: 1.25–5 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 40% · Volume of Distribution (Vd): 490 L · Absorption (ka): 1.5 h⁻¹ (t½ka ≈ 28m)
PK from FDA prescribing information (DailyMed setid 333caafc-2e63-49f8-a0c6-534e528d228d): mean absolute bioavailability ~40% (F 0.4), apparent Vd 7 L/kg (~490 L), elimination t½ ~3 h, Tmax ~1.5 h (tablet). ka_hr 1.5 derived from Tmax 1.5 h (ke from t½ 3 h).